GlassScriptPhysician profile
Sheila M Bien
NPI 1235250366
$1,219.68
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $893 · 2022: $326.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $250.30 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $217.88 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.86 | 2021-2022 | |
| Abbvie INC. | $150.58 | 2021-2022 | |
| Medtronic, INC. | $107.46 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $86.25 | 2021 | |
| Redhill Biopharma INC. | $60.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $47.18 | 2021 | |
| Amgen INC. | $43.71 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $25.51 | 2022 | |
| Lundbeck LLC | $24.64 | 2022 | |
| Lilly USA, LLC | $18.16 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.62 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.96 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Bien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.